紫杉醇联合表阿霉素治疗晚期乳腺癌的临床观察

目的观察紫杉醇联合表阿霉素治疗晚期乳腺癌的疗效和不良反应。方法用紫杉醇联合表阿霉素方案治疗晚期乳腺癌48例,其中初治患者22例,复治患者26例。结果全组总有效率为54.2%。初治患者有效率为54.5%,复治患者有效率为53.8%,初治和复治患者的有效率无显著性差异。全组中位TTP为6.8个月。不良反应以骨髓抑制、脱发、肝损伤和胃肠道反应为主,大多为Ⅰ～Ⅱ度。结论紫杉醇联合表阿霉素对晚期乳腺癌有较好疗效和耐受性,可作为晚期乳腺癌的解救方案。

Clinical observation on palcitaxel and epirubicin in the treatment of advanced breast cancer

Objective To evaluate the efficacy and toxicity of paclitaxel and epirubicin in the treatment of advanced breast cancer.Methods A total of 48 patients with advanced breast cancer proved pathologically were treated on with paclitaxel and epirubicin regimen, among whom 22 patients were subjected to initialy treatment, other 26 to retreatment.Results A total response rate of 54.2% was achieved in the whole cases, with 54.5% in initially treated cases and 53.8% in retreated ones respectively. The median time to progress (TTP) was 6.8 months. Adverse reactions mainly included myelosuppression,alopecia,gastroenteric reaction and hepatotoxicity,all of which were tolerable. Conclusion The regimen of paclitaxel and epirubicin is effective and well-tolerated in the treatment of advanced breast cancer. It may be a relevant regimen for retreated patients.